Baker Tilly served as the accountants and advisors to Osprey Medical, Inc. (Osprey Medical) during their initial public offering (IPO) on the Australian Securities Exchange (ASX). Osprey Medical, a late stage medical device company, successfully raised A$20 million during the IPO and will trade under the ticker "OSP."
Osprey Medical’s lead product, the CINCOR™ System, is designed to reduce kidney injury from x-ray dyes used during common heart procedures such as stenting and angioplasty. Sales in Europe are expected to start in 2012, and the company aims to obtain FDA approval to enable a US market launch in 2014.
"I have been working with Baker Tilly since 2010. On May 2, 2012, the company most recently went public in Australia, and Baker Tilly was integral in the process. Our engagement partner, Mike McKee, and the audit team delivered outstanding service and very timely responses. I really appreciated the detail and expertise that they provided."
Nancy Ness, Vice President of Finance
Osprey Medical, Inc.
Eden Prairie, MN
Baker Tilly works with life sciences companies in every stage of development. Our industry specialization and experience gives us insights into the real and unique challenges they face balancing innovation, productivity, and risk. The professionals on our life sciences team work with you to explore and implement solutions that fit your specific needs. We offer comprehensive tax, accounting, and consulting services that diffuse risk and encourage success.
Contact our life sciences team >